Doximity Surges 52.7% on AI Search Profitability Reveal

What happened

Doximity delivered first-quarter fiscal 2027 results that exceeded Wall Street expectations, posting revenue of $156.6 million and adjusted EBITDA of $74.8 million. The company raised its full-year revenue forecast by $6 million to a range of $671–681 million. During the earnings call, CEO Jeffrey Tangney disclosed that the company's new AI search product earns more than 10 times per search in revenue than it costs to operate, describing the unit economics as exceptional. He added that AI model efficiency improvements could further reduce costs over time. Workflow-active prescribers grew more than 30% year-over-year, and AI Search queries jumped over 25% sequentially, indicating accelerating physician adoption. Net income fell to $24.3 million from $53.3 million a year earlier, and free cash flow declined 34% to $39.6 million as the company invested heavily in growth. Adjusted EBITDA margin compressed seven percentage points to 47.7%. Management forecast next-quarter revenue of $170–171 million, representing roughly 8.9% sequential growth, while trimming the midpoint of full-year adjusted EBITDA guidance from $329 million to $319 million. The company now serves 127 enterprise customers generating more than $500,000 in annual recurring revenue, with net revenue retention of 112% among its top 20 clients.

Why it matters

The AI search profitability disclosure fundamentally alters Doximity's investment narrative. With revenue-to-cost ratios exceeding 10:1, the product demonstrates a scalable, high-margin business model that could significantly expand the company's addressable market in healthcare and pharmaceutical sectors. CEO Tangney described the total addressable market unlocked by AI as a genuine upside surprise. The strong engagement metrics-over 30% growth in workflow-active prescribers and 25% sequential AI query growth-suggest physicians are embedding Doximity's tools into daily workflows, creating stickiness that could drive long-term revenue expansion. Analysts believe management's raised guidance remains conservative and does not fully reflect potential AI search contributions, leaving room for upward revisions. The company's enterprise expansion, with 127 customers exceeding $500,000 in annual recurring revenue and 112% net retention among top clients, reinforces the platform's competitive moat. While near-term profitability metrics weakened as Doximity invests in growth, investors are prioritizing engagement momentum and unit economics over temporary margin compression. If the company converts accelerating AI adoption into sustainable margin expansion, the current valuation-still trading roughly 36.8% below some fair value estimates-could represent significant upside.

Bigger picture

Doximity's AI search success highlights a broader trend of healthcare platforms leveraging artificial intelligence to deepen physician engagement and unlock new revenue streams. The company's ability to monetize AI queries at such favorable unit economics contrasts with many tech firms still struggling to prove AI profitability. The dramatic stock move was amplified by market mechanics: approximately 17% of tradable shares were sold short before the earnings report, and the forced buyback to cover positions created a short squeeze that accelerated gains. Before the rally, Doximity shares had fallen roughly 50% year-to-date, reflecting broader skepticism about healthcare tech valuations. The company's performance suggests that vertical-specific AI applications with clear use cases and strong unit economics can command investor enthusiasm even in a cautious market. Doximity's platform, serving U.S. medical professionals, benefits from network effects and switching costs that create defensible market positions. The sequential revenue growth of nearly 9% and improving enterprise metrics indicate demand is accelerating rather than slowing, countering concerns about healthcare tech spending.

What to watch

Investors should monitor AI search adoption rates and query growth in upcoming quarters to assess whether the 25% sequential increase sustains. Management's ability to convert engagement into revenue without significant margin dilution will be critical-watch whether adjusted EBITDA margins stabilize or expand as AI scales. The updated full-year revenue guidance of $671–681 million sets a baseline, but any further raises would validate the AI opportunity. Enterprise customer growth beyond 127 accounts and net revenue retention trends will signal platform stickiness. Commentary on total addressable market expansion and new use cases for AI tools could provide insight into long-term growth potential. Additionally, short interest levels and broader market sentiment toward healthcare tech will influence near-term price action. Management's next-quarter revenue forecast of $170–171 million implies continued acceleration, so any shortfall would be a negative signal. Finally, watch for analyst revisions following the AI profitability disclosure, as consensus estimates may not yet reflect the new business model.